Bank of America Resumes Coverage on Bristol-Myers (BMY) with a Neutral
BMY Hot Sheet
Rating Summary:5 Buy, 3 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 22
Bank of America resumes coverage on Bristol-Myers (NYSE: BMY) with a Neutral. Price target $22.
To see more analyst ratings on BMY Click Here.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals.
To see more analyst ratings on BMY Click Here.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Piper Jaffray Starts Life Technologies (LIFE) at Neutral
- William Blair Starts EPIQ Systems (EPIQ) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Bank of AmericaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
